{"id":3479,"date":"2025-09-05T16:22:01","date_gmt":"2025-09-05T07:22:01","guid":{"rendered":"https:\/\/atlas.ncc.go.jp\/member_search\/3479"},"modified":"2025-09-05T16:22:03","modified_gmt":"2025-09-05T07:22:03","slug":"Ken-Kato","status":"publish","type":"researcher","link":"https:\/\/atlas.ncc.go.jp\/en\/member_search\/3479","title":{"rendered":"Ken Kato EN"},"template":"","class_list":["post-3479","researcher","type-researcher","status-publish","hentry","en-US"],"acf":{"name_eg":"Ken Kato","familyName_eg":"Kato","has_jp_name":true,"name_jp":"\u52a0\u85e4 \u5065","researcher_photo":2656,"participated_in":["-1"],"degree":"MD, PhD","position":"Chief, Department of Head and Neck, and Esophageal Medical Oncology, and Gastrointestinal Medical Oncology","eg_position":"Chief, Department of Head and Neck, and Esophageal Medical Oncology, and Gastrointestinal Medical Oncology","facilities":3399,"department":["4","13"],"speciality":"Chemotherapy and chemoradiotherapy for oesophageal, esophagogastric, and gastric cancer","eg_speciality":"Chemotherapy and chemoradiotherapy for oesophageal, esophagogastric, and gastric cancer","background":"<h2>Dr. Ken Kato's story<\/h2>\r\n<p>Dr. Ken Kato is a medical oncologist with a primary focus on improving outcomes for patients with oesophageal, esophagogastric, and gastric cancers. His work spans the development of innovative chemotherapies and multimodality treatments for metastatic and early-stage cancers. He has been pivotal in clinical trials, such as JCOG0502, which demonstrated the non-inferiority of chemoradiotherapy to surgery for stage I oesophageal squamous carcinoma, and JCOG1109, a study on neoadjuvant therapy for resectable oesophageal squamous cell carcinoma. He also contributes to international phase III trials involving immune-checkpoint inhibitors. His ultimate goal is to develop advanced therapies and translational research to better serve cancer patients.<\/p>\r\n<h2><strong>Research Interest<\/strong><\/h2>\r\n<ul class=\"list1\">\r\n\t<li>Development of new combination therapies and translational research to improve outcomes for oesophageal cancer patients<\/li>\r\n<\/ul>\r\n<h2><strong>Qualifications, certified physicians, medical specialists<\/strong><\/h2>\r\n<ul class=\"list1\">\r\n\t<li>Medical Oncologist<\/li>\r\n<\/ul>\r\n<h2><strong>Specialized field<\/strong><\/h2>\r\n<ul class=\"list1\">\r\n\t<li>Oesophageal<\/li>\r\n\t<li>Esophagogastric<\/li>\r\n\t<li>Gastric cancer<\/li>\r\n<\/ul>\r\n<h2><strong>Professional Experience<\/strong><\/h2>\r\n<ul class=\"list1\">\r\n\t<li>Chief, Department of Head and Neck, and Esophageal Medical Oncology, and Gastrointestinal Medical Oncology, National Cancer Center Hospital<\/li>\r\n\t<li>Chief, Biobank Translational Research Support Section, Clinical Research Coordinating Section, Clinical Research Support Office, National Cancer Center Hospital<\/li>\r\n<\/ul>","eg_background":"<h2>Dr. Ken Kato's story<\/h2>\r\n<p>Dr. Ken Kato is a medical oncologist with a primary focus on improving outcomes for patients with oesophageal, esophagogastric, and gastric cancers. His work spans the development of innovative chemotherapies and multimodality treatments for metastatic and early-stage cancers. He has been pivotal in clinical trials, such as JCOG0502, which demonstrated the non-inferiority of chemoradiotherapy to surgery for stage I oesophageal squamous carcinoma, and JCOG1109, a study on neoadjuvant therapy for resectable oesophageal squamous cell carcinoma. He also contributes to international phase III trials involving immune-checkpoint inhibitors. His ultimate goal is to develop advanced therapies and translational research to better serve cancer patients.<\/p>\r\n<h2><strong>Research Interest<\/strong><\/h2>\r\n<ul>\r\n\t<li>Development of new combination therapies and translational research to improve outcomes for oesophageal cancer patients<\/li>\r\n<\/ul>\r\n<h2><strong>Qualifications, certified physicians, medical specialists<\/strong><\/h2>\r\n<ul>\r\n\t<li>Medical Oncologist<\/li>\r\n<\/ul>\r\n<h2><strong>Specialized field<\/strong><\/h2>\r\n<ul>\r\n\t<li>Oesophageal<\/li>\r\n\t<li>Esophagogastric<\/li>\r\n\t<li>Gastric cancer<\/li>\r\n<\/ul>\r\n<h2><strong>Professional Experience<\/strong><\/h2>\r\n<ul>\r\n\t<li>Chief, Department of Head and Neck, and Esophageal Medical Oncology, and Gastrointestinal Medical Oncology, National Cancer Center Hospital<\/li>\r\n\t<li>Chief, Biobank Translational Research Support Section, Clinical Research Coordinating Section, Clinical Research Support Office, National Cancer Center Hospital<\/li>\r\n<\/ul>","researcher_outerlink1":"","researcher_outerlink2":"","researcher_outerlink3":"","researcher_outerlink4":"","researcher_outerlink5":"","is_retired":false},"_links":{"self":[{"href":"https:\/\/atlas.ncc.go.jp\/wp-json\/wp\/v2\/researcher\/3479","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atlas.ncc.go.jp\/wp-json\/wp\/v2\/researcher"}],"about":[{"href":"https:\/\/atlas.ncc.go.jp\/wp-json\/wp\/v2\/types\/researcher"}],"acf:post":[{"embeddable":true,"href":"https:\/\/atlas.ncc.go.jp\/wp-json\/wp\/v2\/facility\/3399"}],"wp:attachment":[{"href":"https:\/\/atlas.ncc.go.jp\/wp-json\/wp\/v2\/media?parent=3479"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}